Natazia is an estradiol-based oral contraceptive combining estradiol valerate with the progestin dienogest. Combination oral contraceptives lower the risk of becoming pregnant primarily by suppressing ovulation.
Natazia is specifically indicated for use by women to prevent pregnancy.
Natazia is supplied as a tablet for oral administration. Natazia should be taken in the order directed on the blister pack in order to achieve maximum effectiveness. The first Natazia tablet should be taken orally on Day 1 of the menstrual cycle. A non-hormonal contraceptive should be used as back-up during the first 9 days.
Adverse events associated with the use of Natazia may include, but are not limited to, the following:
Natazia is an estradiol-based oral contraceptive combining estradiol valerate with the progestin dienogest. This is the first in a new class of oral contraceptives to deliver estradiol, the estrogen identical to the one produced by the female body. Combination oral contraceptives lower the risk of becoming pregnant primarily by suppressing ovulation. Other possible mechanisms may include cervical mucus changes that inhibit sperm penetration and endometrial changes that reduce the likelihood of implant ation.
For additional information regarding Natazia or contraceptives, please visit the Natazia web page.
The Natazia (estradiol valerate + dienogest) drug information shown above is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.